Cargando…

Markers of Cellular Proliferation, Apoptosis, Estrogen/Progesterone Receptor Expression and Fibrosis in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids

There appear to be very few data on the exact mechanisms of a selective progesterone receptor modulator action in myomas. The aim of the study was to assess the effects of ulipristal acetate (UPA) on fibroids, especially on estrogen receptor (ER) and progesterone receptor (PR) immunoexpression, prol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szydłowska, Iwona, Grabowska, Marta, Nawrocka-Rutkowska, Jolanta, Piasecka, Małgorzata, Starczewski, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913139/ https://www.ncbi.nlm.nih.gov/pubmed/33546154 http://dx.doi.org/10.3390/jcm10040562

Ejemplares similares

Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids
por: Szydłowska, Iwona, et al.
Publicado: (2021)

Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
por: Szydłowska, Iwona, et al.
Publicado: (2020)

Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate
por: Rabe, Thomas, et al.
Publicado: (2018)

Corrigendum to “Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate”
por: Rabe, Thomas, et al.
Publicado: (2018)

Dietary Natural Compounds and Vitamins as Potential Cofactors in Uterine Fibroids Growth and Development
por: Szydłowska, Iwona, et al.
Publicado: (2022)

Ulipristal acetate, a progesterone receptor modulator for emergency contraception
por: Jadav, Shilpa P., et al.
Publicado: (2012)

Estrogen and Progesterone Receptor Immunoexpression in Fallopian Tubes among Postmenopausal Women Based on Time since the Last Menstrual Period
por: Brodowska, Agnieszka, et al.
Publicado: (2021)

SUN-019 The Selective Progesterone Receptor Modulator Ulipristal Acetate Blocks Glucocorticoid Receptor Transactivation
por: Smalls, Benjamin, et al.
Publicado: (2019)

Ulipristal acetate as a treatment option for uterine fibroids
por: Piecak, Karolina, et al.
Publicado: (2017)

Successful Pregnancy after Treatment with Ulipristal Acetate for Uterine Fibroids
por: Monleón, Javier, et al.
Publicado: (2014)

Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium
por: Whitaker, L.H.R., et al.
Publicado: (2017)

Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
por: Biglia, Nicoletta, et al.
Publicado: (2014)

Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
por: Trefoux Bourdet, Alice, et al.
Publicado: (2015)

Safety after extended repeated use of ulipristal acetate for uterine fibroids
por: Fauser, Bart C. J. M., et al.
Publicado: (2017)

Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France
por: Fernandez, Hervé, et al.
Publicado: (2017)

Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids
por: Middelkoop, Mei-An, et al.
Publicado: (2022)

Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate
por: Kolterud, Åsa, et al.
Publicado: (2022)

Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophin-releasing hormone agonist-sensitive and -resistant uterine fibroids
por: Kim, Eun Hee, et al.
Publicado: (2014)

Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids(†)
por: Ali, Mohamed, et al.
Publicado: (2017)

Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis
por: Geale, Kirk, et al.
Publicado: (2017)

Lymphangioleiomyomatosis with Tuberous Sclerosis Complex—A Case Study
por: Marciniak, Aleksandra, et al.
Publicado: (2023)

Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
por: Ekanem, Emmanuel, et al.
Publicado: (2020)

Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo
por: Horak, Petr, et al.
Publicado: (2012)

The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up
por: Woźniak, Sławomir, et al.
Publicado: (2014)

Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?
por: Odejinmi, Funlayo, et al.
Publicado: (2017)

The use of a short course of Ulipristal Acetate for acute abnormal uterine bleeding in women without uterine fibroids
por: Lambrecht, I, et al.
Publicado: (2023)

Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl(2)-L(1) Expression
por: Esber, Nathalie, et al.
Publicado: (2015)

The Role of Oxidative Stress in the Risk of Cardiovascular Disease and Identification of Risk Factors Using AIP and Castelli Atherogenicity Indicators in Patients with PCOS
por: Nawrocka-Rutkowska, Jolanta, et al.
Publicado: (2022)

Evaluation of the Diagnostic Accuracy of the Interview and Physical Examination in the Diagnosis of Endometriosis as the Cause of Chronic Pelvic Pain
por: Nawrocka-Rutkowska, Jolanta, et al.
Publicado: (2021)

Ulipristal Acetate Interferes With Actin Remodeling Induced by 17β-Estradiol and Progesterone in Human Endometrial Stromal Cells
por: Shortrede, Jorge E., et al.
Publicado: (2018)

Effects of dexamethasone on progesterone and estrogen profiles and uterine progesterone receptor localization during pregnancy in Sahel goat in Semi-Arid region
por: Yahi, Dauda, et al.
Publicado: (2017)

Assessment of the Parameters of Oxidative Stress Depending on the Metabolic and Anthropometric Status Indicators in Women with PCOS
por: Nawrocka-Rutkowska, Jolanta, et al.
Publicado: (2022)

Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management
por: Tsoi, Bernice, et al.
Publicado: (2015)

Phase III long‐term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids
por: Osuga, Yutaka, et al.
Publicado: (2021)

Safety and efficacy of two repeated cycles of ulipristal acetate in the management of symptomatic uterine fibroid among Indian women
por: Jha, Sangam, et al.
Publicado: (2021)

Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics
por: Ali, Mohamed, et al.
Publicado: (2023)

Ulipristal Acetate Efficacy in a Patient with Symptomatic Fibroid and Concomitant Pulmonary Embolism
por: von Wunster, S., et al.
Publicado: (2020)

Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids
por: Morgante, Giuseppe, et al.
Publicado: (2020)

Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids
por: Omar, Mona, et al.
Publicado: (2019)

A Properly Balanced Reduction Diet and/or Supplementation Solve the Problem with the Deficiency of These Vitamins Soluble in Water in Patients with PCOS
por: Szczuko, Małgorzata, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5smb981umr2g24mr9u5fb4psp4